Research ReportsNatco Pharma Q1 Results Review - Setting The Stage For A Strong FY25: ICICI Securities
ADVERTISEMENT
Natco Pharma Q1 Results Review - Setting The Stage For A Strong FY25: ICICI Securities
Gradually improvement in market share of gRevlimid and table pricing in this product had driven ~37% YoY growth in the company's export biz in Q1, says the brokerage.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.